Climb Bio, Inc. entered into an Open Market Sale Agreement with Jefferies LLC on June 12, 2026. The agreement allows for the sale of common stock with an aggregate offering price of up to $100 million. The company simultaneously terminated its previous Equity Distribution Agreement with Oppenheimer & Co. Inc., effective June 11, 2026. No shares were sold under the terminated Oppenheimer agreement, and no termination penalties were incurred. The new offering will be conducted as an at-the-market offering under an existing shelf registration statement.